Sign up to save your podcasts
Or
Share The Mix Tape | Special Edition - Cell and Gene Tx Journey to Commercialization: Drug Development and Manufacturing
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Mix Tape | Special Edition - Cell and Gene Tx Journey to Commercialization: Drug Development and Manufacturing
Welcome back to The Mix Tape! In this 2-part special edition, Mix Talent teamed up with ADVI Health to bring together women leaders in Cell and Gene Therapy to discuss the journey from manufacturing to commercialization. This series will feature insights from our incredible guests on their learnings from past experiences, tips and tricks, and anticipated trends in biotech.
In this episode, Mix Talent's Director of Client Solutions and Scientific Partnerships, Tori Schaefer, is joined by Susan Nichols (President and CEO of Propel Biosciences) and Adora Ndu (Chief Regulatory Officer at BridgeBio) to discuss drug development and manufacturing for cell and gene therapies. Susan and Adora will discuss learnings from past experiences, how to become part of the solution for the future success of cell and gene therapy, the value of the patient community, and their prediction that things are looking up for gene and cell therapy from all corners of the business.
View all episodes
By Mix TalentWelcome back to The Mix Tape! In this 2-part special edition, Mix Talent teamed up with ADVI Health to bring together women leaders in Cell and Gene Therapy to discuss the journey from manufacturing to commercialization. This series will feature insights from our incredible guests on their learnings from past experiences, tips and tricks, and anticipated trends in biotech.
In this episode, Mix Talent's Director of Client Solutions and Scientific Partnerships, Tori Schaefer, is joined by Susan Nichols (President and CEO of Propel Biosciences) and Adora Ndu (Chief Regulatory Officer at BridgeBio) to discuss drug development and manufacturing for cell and gene therapies. Susan and Adora will discuss learnings from past experiences, how to become part of the solution for the future success of cell and gene therapy, the value of the patient community, and their prediction that things are looking up for gene and cell therapy from all corners of the business.